Long-acting HIV therapies have become a major trend in the global HIV treatment landscape, attracting significant investment and strategic positioning from leading multinational pharmaceutical companies. TaiMed Biologics’ TMB-365/380 is the only long-acting HIV regimen composed entirely of monoclonal antibodies. Notably, neither its Phase 2a nor Phase 2b clinical studies required pre-treatment viral susceptibility screening, demonstrating a key differentiating advantage over comparable therapies that typically exclude 30%-50% of patients from treatment eligibility. This distinctive feature has attracted considerable attention within the biotechnology industry.

With the successful completion of Last Patient In (LPI) enrollment in the Phase 2b clinical trial, TMB-365/380 has officially advanced into the later stage of clinical development. This milestone has drawn attention from the global biotechnology industry and was featured in a dedicated report by the U.S.-based life sciences media platform GxPwire.

According to the report, TMB-365/380 has the potential to provide a more convenient long-acting treatment option for HIV maintenance therapy and to establish a meaningful presence in the rapidly expanding market for long-acting HIV treatments.

Related article: https://cgxpwire.com/clinical-trial-research/taimed-advances-long-acting-hiv-therapy-into-late-stage-development/

The report content is as follows:
TaiMed Advances Long-Acting HIV Therapy Into Late-Stage Development TAIPEI, Taiwan, 21 May 2026
TaiMed Biologics announced the completion of enrollment in its Phase 2b clinical study evaluating TMB-365/380, a novel investigational long-acting dual-antibody regimen for HIV maintenance therapy. The study achieved Last Patient In (LPI) ahead of schedule, marking a significant operational milestone for the company as it advances its next-generation HIV treatment platform. TaiMed stated that the program is designed to evaluate the efficacy and safety of TMB-365/380 as an every-two-month (Q2M) maintenance therapy for people living with HIV, potentially offering a more convenient alternative to daily oral antiretroviral regimens.

Phase 2b HIV Study Shows Strong Early Momentum
According to the company, participants enrolled in the Phase 2b trial will continue scheduled follow-up assessments, with an interim data analysis expected by the end of 2026. Preliminary observations from ongoing patient monitoring indicate that viral suppression levels and key biomarkers following the first two treatment doses are consistent with company expectations, supporting continued confidence in the therapy’s clinical potential.

TaiMed believes TMB-365/380 could become the first long-acting broadly neutralizing antibody (bNAb) combination capable of achieving high rates of viral suppression without requiring susceptibility screening before treatment initiation. This distinction could significantly improve patient access and simplify clinical adoption compared with certain existing HIV treatment approaches.
The company stated that, pending positive interim data, it plans to pursue a Breakthrough Therapy Designation (BTD) application with the U.S. Food and Drug Administration to potentially accelerate development and regulatory review timelines.

Long-Acting HIV Therapies Continue Expanding Market Potential
The HIV treatment landscape has increasingly shifted toward long-acting injectable therapies aimed at improving patient adherence, reducing treatment fatigue, and enhancing quality of life. TaiMed estimates that TMB-365/380 could generate peak annual global sales of approximately $3-4 billion, reflecting growing market demand for infrequent-dosing HIV maintenance therapies.
Unlike some currently available long-acting HIV regimens, TaiMed believes its antibody-based therapy may provide broader clinical flexibility by potentially eliminating the need for susceptibility testing prior to treatment selection. This could create a meaningful competitive advantage within the evolving HIV therapeutics market.

Company executives also noted that rapid patient enrollment highlights strong interest from both investigators and clinical sites in long-acting HIV treatment options. The accelerated enrollment pace may reflect increasing physician and patient demand for alternatives to conventional daily oral therapy.

TaiMed Explores Global Partnerships and Commercial Expansion
TaiMed Biologics is actively exploring strategic partnerships, including licensing and co-development agreements, to support the future global commercialization of TMB-365/380. The company already has commercial experience in HIV biologics through Trogarzo (ibalizumab), the first and only FDA-approved monoclonal antibody therapy for HIV treatment.
Founded in 2007, TaiMed operates as a commercial-stage biotechnology company focused primarily on HIV innovation and biologics development. In addition to its HIV pipeline, the company also provides contract development and manufacturing organization (CDMO) services and continues expanding its global biotechnology footprint.

The successful completion of enrollment in the TMB-365/380 Phase 2b study positions TaiMed for a potentially important catalyst later this year as investors and clinicians await interim efficacy and safety results that could shape the next phase of development.
Back to the top